Becton Dickinson in its plan to pursue a separation of its Biosciences and Diagnostic Solutions business

On February 5, 2025, BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that its board of directors has unanimously authorized management to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions business from the rest of BD. The separation decision was the result of a comprehensive business portfolio evaluation launched by BD in early 2024.

Wachtell, Lipton, Rosen & Katz is serving as legal advisor to BD.